Related Experiment Videos
Assay for human matrix gla protein in serum: potential applications in the cardiovascular field
L A Braam1, P Dissel, B L Gijsbers
1Department of Biochemistry, University of Maastricht, The Netherlands.
Abstract:
Matrix Gla protein (MGP) is synthesized in a vitamin K-dependent way in smooth muscle cells of the healthy vessel wall, and its mRNA transcription is substantially upregulated in atherosclerotic lesions. Here we report the preparation of a monoclonal antibody against human MGP and its use in an enzyme-linked immunosorbent assay. The intra-assay and interassay coefficients of variation in serum samples were 5.4% and 12.6%, respectively, and the lower detection limit was 8.5% of the normal serum value. Individual within-day variations were <11% and did not show a distinct circadian pattern. Day-to-day variations in fasting morning samples were <8%. In a first explorative survey, serum MGP concentrations were found to be significantly increased in patients with severe atherosclerosis, whereas these values were normal in those with low bone mass and osteoporosis. This finding is consistent with the high MGP mRNA expression observed in atherosclerotic vessels and plaques. More elaborate studies are required to assess the potential clinical utility of this newly developed assay.
Insights
Serum Matrix Gla protein (MGP) levels are elevated in severe atherosclerosis patients. This study developed a new assay to measure MGP, finding increased concentrations linked to vascular disease, not bone conditions.
Area of Science:
- Biochemistry
- Vascular Biology
- Immunology
Background:
- Matrix Gla protein (MGP) is vitamin K-dependent, produced by smooth muscle cells.
- MGP mRNA is significantly upregulated in atherosclerotic lesions.
- MGP plays a role in vascular calcification and vessel wall health.
Purpose of the Study:
- To develop a monoclonal antibody and an enzyme-linked immunosorbent assay (ELISA) for human MGP.
- To validate the assay's performance characteristics.
- To investigate serum MGP concentrations in patients with atherosclerosis and bone conditions.
Main Methods:
- Preparation of a monoclonal antibody against human MGP.
- Development and validation of an MGP-specific ELISA.
- Measurement of serum MGP in patient cohorts (atherosclerosis, osteoporosis).
Main Results:
- The MGP assay demonstrated good intra-assay (5.4%) and inter-assay (12.6%) variability.
- The assay had a low detection limit (8.5% of normal serum value).
- Serum MGP was significantly increased in severe atherosclerosis patients but normal in osteoporosis patients.
Conclusions:
- The developed MGP assay is reliable for measuring serum MGP levels.
- Elevated serum MGP is associated with severe atherosclerosis, consistent with MGP's role in vascular health.
- Further studies are needed to determine the clinical utility of this MGP assay in vascular disease management.